<p>MDxHealth SA（纳斯达克代码：MDXH - 获取免费报告）在 12 月份的空头头寸显著增长。截至 12 月 31 日，空头头寸总计 39,441 股，比 12 月 15 日的 15,027 股增长了 162.5%。根据 115,122 股的平均交易量，当前的覆盖天数比率为 0.3 天。目前，公司 0.1% 的股份被卖空。目前，公司 0.1% 的股份被卖空。根据 115,122 股的平均交易量，当前的覆盖天数比率为 0.3 天。</p>
<h2>MDxHealth 价格表现</h2>
<p>纳斯达克 MDXH 周三开盘价为 3.61 美元。该股票的 50 日移动平均线为 3.56 美元，200 日移动平均线为 3.49 美元。MDxHealth 的年内最低价为 1.35 美元，年内最高价为 5.33 美元。该公司的市值为 1.7072 亿美元，市盈率为-5.64，贝塔值为 1.62。</p>
<p>MDxHealth（纳斯达克代码：MDXH - 获取免费报告）最近一次公布财报是在 11 月 12 日，报告显示该季度每股收益为（0.16 美元），低于市场共识预期的（0.12 美元）4 美分。该季度的收入为 2743 万美元，而分析师预期为 2411 万美元。MDxHealth 的股本回报率为-1,078.01%，净利润率为-30.50%。股票分析师预计 MDxHealth 在当前年度的每股收益为-1.15 美元。</p>
<h2>MDxHealth 的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近调整了对 MDXH 的持股。FreeGulliver LLC 在第二季度新购入 MDxHealth 的股份，价值约 273,000 美元。Calamos Advisors LLC 在第三季度购买了 MDxHealth 的新股份，价值约 305,000 美元。GSA Capital Partners LLP 在第三季度新购入 MDxHealth 的股份，价值约 48,000 美元。Jefferies Financial Group Inc.在第三季度新购入 MDxHealth 的股份，价值约 53,000 美元。最后，Russell Investments Group Ltd.在第三季度新购入 MDxHealth 的股份，价值约 461,000 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家券商对 MDXH 进行了评估。TD Cowen 在 11 月 13 日的报告中将 MDxHealth 的目标价从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。Lake Street Capital 在 11 月 13 日的研究报告中将 MDxHealth 的目标价从 7.00 美元上调至 9.00 美元，并给予该股票 “买入” 评级。BTIG Research 在 12 月 23 日的报告中重申了对 MDxHealth 的 “买入” 评级，并给出了 7.00 美元的目标价。最后，Weiss Ratings 在 12 月 29 日的报告中重申了对 MDxHealth 的 “卖出（d-）” 评级。四位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 7.75 美元。</p>
<p><strong>查看我们最新的 MDXH 股票分析</strong></p>
<h2>关于 MDxHealth</h2>
<p>（获取免费报告）</p>
<p>MDxHealth 总部位于比利时梅赫伦，在美国马萨诸塞州牛顿设有办事处，是一家分子诊断公司，专注于通过表观遗传生物标志物检测提高癌症诊断和治疗决策的准确性。该公司专注于开发和商业化检测与泌尿系统癌症相关的 DNA 甲基化变化的测试，从而实现更精确的风险分层和患者管理。</p>
<p>MDxHealth 的主要产品组合包括 ConfirmMDx 和 SelectMDx。</p>
<h2>相关文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 MDxHealth</li>
<li>埃隆将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>将这些代码输入您的普通经纪账户</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
<li>股票即将迎来 “凶兆日”...</li>
<li>崩盘前一个月</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 MDxHealth 吗？</h2>
<p>在考虑 MDxHealth 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买...而 MDxHealth 并不在名单上。</p>
<p>虽然 MDxHealth 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDXH

<p>MDxHealth SA (NASDAQ:MDXH) 在 12 月份的空头头寸显著增加，增长了 162.5%，达到 39,441 股。当前的空头头寸比率为 0.3 天，卖空股份占 0.1%。该股票开盘价为 3.61 美元，市值为 1.7072 亿美元，市盈率为-5.64。分析师的评级意见不一，普遍评级为 “适度买入”，平均目标价为 7.75 美元。该公司专注于癌症诊断和治疗的分子诊断</p>

<p>MDxHealth SA (NASDAQ:MDXH - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 39,441 shares, a growth of 162.5% from the December 15th total of 15,027 shares. Based on an average trading volume of 115,122 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the company's shares are sold short. Currently, 0.1% of the company's shares are sold short. Based on an average trading volume of 115,122 shares, the days-to-cover ratio is presently 0.3 days.</p>
<div class="lb-trans"><p>MDxHealth SA（纳斯达克代码：MDXH - 获取免费报告）在 12 月份的空头头寸显著增长。截至 12 月 31 日，空头头寸总计 39,441 股，比 12 月 15 日的 15,027 股增长了 162.5%。根据 115,122 股的平均交易量，当前的覆盖天数比率为 0.3 天。目前，公司 0.1% 的股份被卖空。目前，公司 0.1% 的股份被卖空。根据 115,122 股的平均交易量，当前的覆盖天数比率为 0.3 天。</p>
</div><h2>MDxHealth Price Performance</h2>
<div class="lb-trans"><h2>MDxHealth 价格表现</h2>
</div><p>NASDAQ MDXH opened at $3.61 on Wednesday. The stock's 50-day moving average is $3.56 and its 200-day moving average is $3.49. MDxHealth has a one year low of $1.35 and a one year high of $5.33. The firm has a market cap of $170.72 million, a P/E ratio of -5.64 and a beta of 1.62.</p>
<div class="lb-trans"><p>纳斯达克 MDXH 周三开盘价为 3.61 美元。该股票的 50 日移动平均线为 3.56 美元，200 日移动平均线为 3.49 美元。MDxHealth 的年内最低价为 1.35 美元，年内最高价为 5.33 美元。该公司的市值为 1.7072 亿美元，市盈率为-5.64，贝塔值为 1.62。</p>
</div><p>MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $27.43 million for the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%. Equities analysts anticipate that MDxHealth will post -1.15 EPS for the current year.</p>
<div class="lb-trans"><p>MDxHealth（纳斯达克代码：MDXH - 获取免费报告）最近一次公布财报是在 11 月 12 日，报告显示该季度每股收益为（0.16 美元），低于市场共识预期的（0.12 美元）4 美分。该季度的收入为 2743 万美元，而分析师预期为 2411 万美元。MDxHealth 的股本回报率为-1,078.01%，净利润率为-30.50%。股票分析师预计 MDxHealth 在当前年度的每股收益为-1.15 美元。</p>
</div><h2>Institutional Trading of MDxHealth</h2>
<div class="lb-trans"><h2>MDxHealth 的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of MDXH. FreeGulliver LLC acquired a new position in shares of MDxHealth during the second quarter worth about $273,000. Calamos Advisors LLC bought a new stake in MDxHealth in the 3rd quarter valued at approximately $305,000. GSA Capital Partners LLP acquired a new position in MDxHealth during the 3rd quarter worth approximately $48,000. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the 3rd quarter worth approximately $53,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of MDxHealth in the third quarter valued at approximately $461,000.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对 MDXH 的持股。FreeGulliver LLC 在第二季度新购入 MDxHealth 的股份，价值约 273,000 美元。Calamos Advisors LLC 在第三季度购买了 MDxHealth 的新股份，价值约 305,000 美元。GSA Capital Partners LLP 在第三季度新购入 MDxHealth 的股份，价值约 48,000 美元。Jefferies Financial Group Inc.在第三季度新购入 MDxHealth 的股份，价值约 53,000 美元。最后，Russell Investments Group Ltd.在第三季度新购入 MDxHealth 的股份，价值约 461,000 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several brokerages have weighed in on MDXH. TD Cowen boosted their price objective on MDxHealth from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, November 13th. Lake Street Capital boosted their price target on shares of MDxHealth from $7.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. BTIG Research restated a &#34;buy&#34; rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of MDxHealth in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $7.75.</p>
<div class="lb-trans"><p>几家券商对 MDXH 进行了评估。TD Cowen 在 11 月 13 日的报告中将 MDxHealth 的目标价从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。Lake Street Capital 在 11 月 13 日的研究报告中将 MDxHealth 的目标价从 7.00 美元上调至 9.00 美元，并给予该股票 “买入” 评级。BTIG Research 在 12 月 23 日的报告中重申了对 MDxHealth 的 “买入” 评级，并给出了 7.00 美元的目标价。最后，Weiss Ratings 在 12 月 29 日的报告中重申了对 MDxHealth 的 “卖出（d-）” 评级。四位股票研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 7.75 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on MDXH</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 MDXH 股票分析</strong></p>
</div><h2>About MDxHealth</h2>
<div class="lb-trans"><h2>关于 MDxHealth</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.</p>
<div class="lb-trans"><p>MDxHealth 总部位于比利时梅赫伦，在美国马萨诸塞州牛顿设有办事处，是一家分子诊断公司，专注于通过表观遗传生物标志物检测提高癌症诊断和治疗决策的准确性。该公司专注于开发和商业化检测与泌尿系统癌症相关的 DNA 甲基化变化的测试，从而实现更精确的风险分层和患者管理。</p>
</div><p>MDxHealth's lead product portfolio includes ConfirmMDx and SelectMDx.</p>
<div class="lb-trans"><p>MDxHealth 的主要产品组合包括 ConfirmMDx 和 SelectMDx。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than MDxHealth</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>“Ominous day” coming to stocks…</li>
<li>A month before the crash</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MDxHealth</li>
<li>埃隆将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>将这些代码输入您的普通经纪账户</li>
<li>崩盘已经开始（大多数人还未察觉）</li>
<li>股票即将迎来 “凶兆日”...</li>
<li>崩盘前一个月</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MDxHealth Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MDxHealth 吗？</h2>
</div><p>Before you consider MDxHealth, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MDxHealth 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买...而 MDxHealth 并不在名单上。</p>
</div><p>While MDxHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MDxHealth 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MDxHealth SA（NASDAQ:MDXH）空头头寸显著增加